These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 38955109)

  • 1. Letter to the Editor: "Exploring long-term responses to immune checkpoint inhibitors in recurrent and metastatic head and neck squamous cell Carcinoma".
    Haridevamuthu B
    Oral Oncol; 2024 Sep; 156():106913. PubMed ID: 38955109
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of antibiotics on PD-1 inhibition in recurrent/metastatic head and neck squamous cell carcinoma.
    Knap Rabjerg H; Grau Eriksen J; Søby S
    Oral Oncol; 2024 Nov; 158():107003. PubMed ID: 39180815
    [No Abstract]   [Full Text] [Related]  

  • 3. Letter to the editor "A phase 1 study of concurrent cabozantinib and cetuXimab in recurrent or metastatic head and neck squamous cell cancer".
    Tamil Selvan S
    Oral Oncol; 2024 Oct; 157():106958. PubMed ID: 39059049
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea.
    Kim H; Kwon M; Kim B; Jung HA; Sun JM; Lee SH; Park K; Ahn MJ
    BMC Cancer; 2020 Aug; 20(1):727. PubMed ID: 32758163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The immune checkpoint inhibitors treatment of head and neck squamous cell carcinoma: an expert consensus.
    Liu L; Xiang Z; Li Y; Guo W; Yang K; Wang J; Sun Z; Ren G; Zhang J; Sun M; Ran W; Huang G; Tang Z; Li L
    Hua Xi Kou Qiang Yi Xue Za Zhi; 2022 Dec; 40(6):619-628. PubMed ID: 36416313
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
    Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
    Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitor use in head and neck squamous cell carcinoma: the current landscape and future perspectives.
    Gatfield ER; Tadross J; Ince W
    Future Oncol; 2024; 20(23):1695-1711. PubMed ID: 38889284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune-checkpoint inhibitors versus other systemic therapies in advanced head and neck cancer: a network meta-analysis.
    Tang L; Liu T; Chen J; Dang J; Li G
    Immunotherapy; 2021 Apr; 13(6):541-555. PubMed ID: 33629592
    [No Abstract]   [Full Text] [Related]  

  • 10. De novo metastatic head and neck squamous cell carcinoma: Why does locoregional control "always" matter?
    Lorini L; Gili R; Salvestrini V; Morelli I; Smussi D; Petrelli F; Bonomo P; Bossi P
    Oral Oncol; 2024 May; 152():106768. PubMed ID: 38552469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to salvage chemotherapy after progression on immune checkpoint inhibitors in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Saleh K; Daste A; Martin N; Pons-Tostivint E; Auperin A; Herrera-Gomez RG; Baste-Rotllan N; Bidault F; Guigay J; Le Tourneau C; Saada-Bouzid E; Even C
    Eur J Cancer; 2019 Nov; 121():123-129. PubMed ID: 31574417
    [TBL] [Abstract][Full Text] [Related]  

  • 12. No prime time yet for checkpoint inhibitors in localised head and neck squamous cell carcinoma.
    Voortman J
    Lancet Oncol; 2024 May; 25(5):533-534. PubMed ID: 38697152
    [No Abstract]   [Full Text] [Related]  

  • 13. Proton pump inhibitors and antibiotics adversely effect the efficacy of nivolumab in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
    Wada A; Enokida T; Okano S; Sato M; Tanaka H; Ueda Y; Fujisawa T; Takeshita N; Tanaka N; Tahara M
    Eur J Cancer; 2023 May; 184():30-38. PubMed ID: 36898232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcomes of Cetuximab and Paclitaxel after Progression on Immune Checkpoint Inhibitors in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Suzuki S; Toyoma S; Kawasaki Y; Koizumi K; Iikawa N; Shiina K; Endo T; Abe T; Kouga T; Yamada T
    Medicina (Kaunas); 2021 Oct; 57(11):. PubMed ID: 34833369
    [No Abstract]   [Full Text] [Related]  

  • 15. Efficacy of Nivolumab and Pembrolizumab in Platinum-sensitive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
    Yamashita G; Okamoto I; Ito T; Tokashiki K; Okada T; Tsukahara K
    Anticancer Res; 2023 Aug; 43(8):3679-3683. PubMed ID: 37500154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overall survival and PD-L1 expression in patients with recurrent or metastatic head and neck cancer treated with nivolumab.
    Okamoto I; Sato H; Tsukahara K
    Auris Nasus Larynx; 2020 Aug; 47(4):676-686. PubMed ID: 32439271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastasis in head and neck squamous cell carcinoma after immune check point inhibitors treatment.
    Lorini L; Merlano M; Licitra L; Ravanelli M; Bossi P
    Oral Oncol; 2021 May; 116():105138. PubMed ID: 33390267
    [No Abstract]   [Full Text] [Related]  

  • 19. Systemic treatment of recurrent and/or metastatic squamous cell carcinomas of the head and neck: what is the best therapeutic sequence?
    Saada-Bouzid E; Peyrade F; Guigay J
    Curr Opin Oncol; 2022 May; 34(3):196-203. PubMed ID: 35671120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are immune checkpoint inhibitors ineffective in treating patients with head and neck squamous cell carcinoma aged 75 years or Older? A Meta-Analysis.
    Zhang S; Zheng M; Tian H; Liu W; Feng Z; Xing S; Han F
    Oral Oncol; 2024 Jan; 148():106632. PubMed ID: 38039875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.